The use of first-generation tyrosine kinase inhibitors in patients with NSCLC and somatic EGFR mutations

Lung Cancer

Volumn 60, Issue SUPPL. 2, 2008, Pages

  Riely, Gregory J ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Activating mutations; Epidermal growth factor receptor; Erlotinib; Gefitinib; Mutation profile; Non small cell lung cancer

Indexed keywords

CARBOPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; PACLITAXEL; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR;

ADENOCARCINOMA; ARTICLE; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG EFFECT; DRUG SENSITIVITY; GENE DELETION; GENETIC ASSOCIATION; HUMAN; LUNG NON SMALL CELL CANCER; MUTATIONAL ANALYSIS; OUTCOME ASSESSMENT; PATHOGENESIS; PRIORITY JOURNAL; SOMATIC MUTATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

CARCINOMA, NON-SMALL-CELL LUNG; DRUG RESISTANCE, NEOPLASM; HUMANS; LUNG NEOPLASMS; MUTATION; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 44249121487     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(08)70101-6     Document Type: Article

References (24)

1. Giaccone G., and Rodriguez J. EGFR inhibitors: what have we learned from the treatment of lung cancer?. Nat Clin Pract Oncol 2 11 (2005) 554-561
2. Shepherd F., Rodrigues Pereira J., Ciuleanu T., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353 2 (2005) 123-132
3. Lynch T., Bell D., Sordella R., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350 21 (2004) 2129-2139
4. Paez J., Janne P., Lee J., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304 5676 (2004) 1497-1500
5. Pao W., Miller V., Zakowski M., et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumours to gefitinib and erlotinib. Proc Natl Acad Sci U S A 101 36 (2004) 13306-13311
6. Pao W., and Miller V. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J Clin Oncol 23 11 (2005) 2556-2568
7. Miller V., Kris M., Shah N., et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol 22 6 (2004) 1103-1109
8. Riely G., Politi K., Miller V., et al. Update on epidermal growth factor receptor mutations in non-small cell lung cancer. Clin Cancer Res 12 24 (2006) 7232-7241
9. Weinstein I. Cancer. Addiction to oncogenes-the Achilles heal of cancer. Science 297 5578 (2002) 63-64
10. Weinstein I., and Joe A. Mechanisms of disease: Oncogene addiction-a rationale for molecular targeting in cancer therapy. Nat Clin Pract Oncol 3 8 (2006) 448-457
11. Tsao M., Sakurada A., Cutz J., et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 353 2 (2005) 133-144
12. Eberhard D., Johnson B., Amler L., et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 23 25 (2005) 5900-5909
13. Miller V., Riely G., Zakowski M., et al. Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. J Clin Oncol 26 9 (2008) 1472-1478
14. Sequist L., Martins R., Spigel D., et al. iTARGET: A phase II trial to assess the response to gefitinib in epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) tumours. J Clin Oncol 25 18S (2007) 7504
15. Haneda H., Sasaki H., Lindeman N., et al. A correlation between EGFR gene mutation status and bronchioloalveolar carcinoma features in Japanese patients with adenocarcinoma. Jpn J Clin Oncol 36 2 (2006) 69-75
16. Na I., Rho J., Choi Y., et al. The survival outcomes of patients with resected non-small cell lung cancer differ according to EGFR mutations and the P21 expression. Lung Cancer 57 1 (2007) 96-102
17. Riely G., Pao W., Pham D., et al. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res 12 3 Pt 1 (2006) 839-844
18. Jackman D., Yeap B., Sequist L., et al. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res 12 13 (2006) 3908-3914
19. Balak M., Gong Y., Riely G., et al. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res 12 21 (2006) 6494-6501
20. Bean J., Brennan C., Shih J., et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumours with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A 104 52 (2007) 20932-20937
21. Engelman J., Zejnullahu K., Mitsudomi T., et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316 5827 (2007) 1039-1043
22. Kobayashi S., Boggon T., Dayaram T., et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352 8 (2005) 786-792
23. Pao W., Miller V., Politi K., et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2 3 (2005) e73
24. Riely G., Kris M., Zhao B., et al. Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus. Clin Cancer Res 13 17 (2007) 5150-5155